Jean-Pierre Issa
Molecular Biology · 2004–2019
A researcher in the Science corpus: 11 papers; trusts 7 researchers and is trusted by 7 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 153 citations into it; #5,147 of 17,773 by trust here, #4,474 by citations
- Genetics — 60 citations into it; #2,041 of 6,854 by trust here, #4,339 by citations
- Oncology — 39 citations into it
- Pathology and Forensic Medicine — 10 citations into it
Whom Jean-Pierre Issa trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- A. Bird
- Peter A. Jones
- D. Sidransky
- R. Jaenisch
- S. Baylin
- Gerda Egger
- Peter W. Laird
- Lawrence Loeb
- J. Herman
Who trusts Jean-Pierre Issa overall
- Peter W. Laird
- Melanie Ehrlich
- S. Baylin
- Keith D. Robertson
- Eric R. Fearon
- Mingzhao Xing
- Peter A. Jones
Papers from Jean-Pierre Issa's perspective
Ordered by how strongly the researchers Jean-Pierre Issa trusts endorse each paper. Same corpus, a different order for every researcher.
- A bivalent chromatin structure marks key developmental genes in embryonic stem cells. (Cell)
- The fundamental role of epigenetic events in cancer (Nature reviews genetics)
- DNA methylation patterns and epigenetic memory.
- A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing (Nature Genetics)
- Hallmarks of cancer: the next generation. (Cell)
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 (Science)
- Epigenetic stem cell signature in cancer (Nature Genetics)
- Epigenetics in human disease and prospects for epigenetic therapy (Nature)
- Induction of Tumors in Mice by Genomic Hypomethylation (Science)
- Human DNA methylomes at base resolution show widespread epigenomic differences
Their papers
- Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation (2008) — 641 citations
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. (2004) — 825 citations
- Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012) — 614 citations
- A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. (2004) — 1,031 citations
- Decitabine improves patient outcomes in myelodysplastic syndromes (2006) — 1,571 citations
- Dnmt3a is essential for hematopoietic stem cell differentiation (2011) — 1,105 citations
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007) — 718 citations
- CpG island methylator phenotype in cancer (2004) — 1,085 citations
- Targeting the cancer epigenome for therapy (2016) — 1,011 citations
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) — 634 citations
- DNA methylation aging clocks: challenges and recommendations (2019) — 841 citations